Total | Male | Female | |||||||
---|---|---|---|---|---|---|---|---|---|
β | 95%-CI | p-value | β | 95%-CI | p-value | β | 95%-CI | p-value | |
FEV1a | |||||||||
SHS exposureb | −44 | (−82, −5) | 0.03 | −75 | (− 140, − 11) | 0.02 | −13 | (− 57, 31) | 0.56 |
SHS exposure*follow-up timec | 1 | (0, 3) | 0.03 | 2 | (0, 4) | 0.03 | 1 | (−1, 3) | 0.19 |
FVCa | |||||||||
SHS exposureb | − 56 | (−102, − 10) | 0.02 | − 102 | (− 179, − 24) | 0.01 | −19 | (−71, 33) | 0.47 |
SHS exposure*follow-up timec | 2 | (0, 4) | 0.02 | 3 | (0, 6) | 0.03 | 2 | (0, 4) | 0.09 |
FEV1/FVCa | |||||||||
SHS exposureb | 0.0 | (− 0.5, 0.5) | 0.96 | 0.1 | (− 0.6, 0.9) | 0.71 | 0.1 | (−0.6, 0.7) | 0.88 |
SHS exposure*follow-up timec | 0.0 | (0.0, 0.0) | 0.94 | 0.0 | (0.0, 0.0) | 0.96 | 0.0 | (0.0, 0.0) | 0.62 |